Skip to main content

Table 2 IMR data and cytokine levels

From: The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease

 

Patient group vs control group

Patient group

Controls (N = 26)

Patients (N = 74)

P

aMCI (N = 35)

AD (N = 39)

P

1-40

50.7 ± 4.9

52.1 ± 4.2

0.160

51.9 ± 4.8

52.3 ± 3.7

0.654

1-42

16.9 ± 0.7

17.3 ± 1.0

0.038

17.2 ± 1.1

17.4 ± 0.9

0.455

t-Tau

23.8 ± 3.9

26.6 ± 5.1

0.014

26.0 ± 5.1

27.1 ± 5.2

0.374

p-Tau181

3.7 ± 0.7

4.1 ± 0.9

0.035

4.0 ± 0.9

4.2 ± 0.9

0.340

IL-1β

0.07 ± 0.04

0.12 ± 0.11

0.039

0.12 ± 0.11

0.12 ± 0.12

0.765

IL-1RA

63 ± 31

96 ± 79

0.045

108 ± 104

85 ± 45

0.289

  1. Abbreviation: aMCI mild cognitive impairment due to Alzheimer’s disease, AD Alzheimer’s disease, IL interleukin; IL-1RA interleukin 1 receptor antagonist